Xilio Therapeutics (XLO) Change in Accured Expenses (2020 - 2026)

Xilio Therapeutics has disclosed Change in Accured Expenses across 7 years of filings, most recently posting -$1.5 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.5 million, up 75.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (up 171.18% YoY), and the FY2025 annual result was -$979000.0, up 36.55% from the prior year.
• Change in Accured Expenses came in at -$1.5 million for Q1 2026 at Xilio Therapeutics, down from $928000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.6 million in Q2 2022 to a low of -$6.4 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $664000.0 (2023), against an average of -$135176.5.
• Across the five-year window, Change in Accured Expenses sank 929.33% in 2022 and jumped 1669.67% in 2025, its largest moves.
• Xilio Therapeutics' Change in Accured Expenses stood at $1.5 million in 2022, then slipped by 24.91% to $1.1 million in 2023, then tumbled by 107.71% to -$85000.0 in 2024, then soared by 1191.76% to $928000.0 in 2025, then tumbled by 265.52% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $928000.0 (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.